Headquartered in Waltham, MA·Fiscal year ends December·NASDAQ: ARDX·ardelyx.com
About Ardelyx
Ardelyx is a commercial-stage biopharmaceutical company that develops and commercializes medicines for significant unmet medical needs. It has two FDA-approved, first-in-class products in the United States, both based on tenapanor.
- IBSRELA treats irritable bowel syndrome with constipation (IBS-C) in adults. It is the company's main growth driver, and Ardelyx has a long-term goal of $1 billion in annual revenue for the product.
- XPHOZAH reduces serum phosphorus in adults with chronic kidney disease on dialysis. It is used as add-on therapy for patients who respond inadequately to, or cannot tolerate, phosphate binders.
The pipeline includes:
- The fully enrolled Phase 3 ACCEL trial of tenapanor in chronic idiopathic constipation, with topline data expected in the second half of 2027.
- RDX10531, a next-generation NHE3 inhibitor in IND-enabling studies.
- Pediatric programs in IBS-C and functional constipation.
Ardelyx relies on partners to develop and commercialize its products outside the United States. It earns product supply, licensing and royalty revenue from these arrangements. U.S. sales are supported by a field force, a shift toward specialty pharmacy, and a direct-to-consumer advertising campaign for IBSRELA. Updated
24/7 Wall St. looks at some big analyst calls that we have seen so far on Tuesday, including Apple, Array Technologies, CareDx and Vertex Pharmaceuticals.
Ardelyx is a commercial-stage biopharmaceutical company that develops and commercializes medicines for significant unmet medical needs. It has two FDA-approved, first-in-class products in the United States, both based on tenapanor. - IBSRELA treats irritable bowel syndrome with constipation (IBS-C) in adults.
What is the ARDX stock price target?
The Wall Street consensus 12-month price target for ARDX is $12.50.